Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€13.10

€13.10

0.770%
0.1
0.770%
€20.11

€20.11

 
16:45 / Tradegate WKN: A2JDYX / Symbol: EOLS / Name: Evolus / Stock / Biotechnology & Medical Research / Small Cap /
Latest predictions
€20.00
14:39
-1.53%
buy
€24.90
01.03.24
-4.38%
buy
€14.78
29.01.24
11.02%
buy
€24.85
17.01.24
18.02%
buy
€20.07
20.12.23
50.57%
buy
€20.11
03.08.23
42.39%
buy
Best running prediction
€20.07
20.12.23
50.57%
buy
Your prediction

Evolus Inc Stock

Evolus Inc gained 0.770% compared to yesterday.
Evolus Inc is currently one of the favorites of our community with 6 Buy predictions and no Sell predictions.
As a result the target price of 20 € shows a very positive potential of 52.67% compared to the current price of 13.1 € for Evolus Inc.
For the coming years our community has positive and negative things to say abot the Evolus Inc stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.

Pros and Cons of Evolus Inc in the next few years

Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Evolus Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Evolus Inc 0.770% 1.563% -2.985% 66.667% 39.037% 31.287% -
Salarius Pharmaceuticals Inc. 1.470% -21.538% -20.000% -76.920% -26.486% -98.684% -99.992%
Ardelyx Inc. 0.870% -3.641% -22.870% 71.742% 19.031% 28.024% -
Brainstorm Cell -15.440% 23.377% 72.727% -61.668% 145.690% -82.407% -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-06-29

Upon an initial overview of the financials of Evolus Inc. (EOLS), a bio-tech and medical research company, it's evident that there are both strong and weak points to consider. Considering the financial data spanning across the past three fiscal years, including some quarterly numbers in 2023, it draws a multifaceted financial landscape.

A positive aspect gleaned from the company's income statements is a rising gross profit margin, growing from $38.2 million in 2020 to $92.7 million in 2022. This amplification reflects the company's ability to effectively manage costs related to goods sold, marking a positive trend in cost efficiency.

Though the company's retained earnings have been in a deficit, indicating more accumulated losses than profits, it's important to reference the pattern of decreasing net losses from a drastic -$163 million in 2020 to a lesser -$74.4 million by 2022. This trajectory proposes that the company's strategy in minimizing losses is at least cursorily effective.

Comments

Prediction Buy
Perf. (%) -4.38%
Target price 24.905
Change
Ends at 01.03.25

Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 11.02%
Target price 14.784
Change
Ends at 29.01.25

Evolus, Inc. (NASDAQ: EOLS) was upgraded by analysts at Barclays PLC from an "equal weight" rating to an "overweight" rating. They now have a $16.00 price target on the stock, up previously from $10.00.
Ratings data for EOLS provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 18.02%
Target price 24.845
Change
Ends at 17.01.25

Evolus, Inc. (NASDAQ: EOLS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $27.00 price target on the stock.
Ratings data for EOLS provided by MarketBeat
Show more